A Phase 1 interventional study of Microgynon and GSK3036656 in Tuberculosis, sponsored by GlaxoSmithKline. Completed at 1 site in Spain. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-26.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Tuberculosis by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Tuberculosis · GlaxoSmithKline.
Among the 21 studies in Tuberculosis by GlaxoSmithKline, this one is the 18th largest by enrollment, is the only one that started in 2024, is one of 8 in phase 1, and was the 20th registered.
1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.
Browse Tuberculosis studies →1 of the 21 studies in Tuberculosis by GlaxoSmithKline is open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Spain
Ages 18–64 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 65 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 150 across 820 interventional studies indexed under Tuberculosis.
Median enrollment 50 across the 21 interventional studies. Of the 20 that completed or were terminated, 14 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Tuberculosis by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07784894GlaxoSmithKlineA Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing Potential | 2026-11-17 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Tuberculosis by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide data showing if there are any effects of GSK3036656 on a combined oral contraceptive containing Ethinyl Estradiol (EE) and Levonorgestrel (LNG), which will help inform future studies on suitable contraceptive measures to be used.
Inclusion Criteria:
Age:
Participant was 18 to 65 years of age, inclusive, at the time of signing the .
Type of Participant and Disease Characteristics:
Echocardiogram was normal or showed normal left ventricular function; at most trace to mild valvular regurgitation was allowed, with no valvular stenosis.
Weight:
Body weight was >= 45.0 kg (99 lbs), and was within the range 18.5 to 31.0 kg/m² (inclusive).
Sex:
Female participants were of Nonchildbearing Potential (WONCBP).
Women in the following categories were considered WONCBP:
Permanently sterile due to one of the following procedures:
females. A postmenopausal state was defined as no menses for 12 months without an alternative medical cause.
Informed Consent:
Exclusion Criteria:
Medical History:
History of known cardiac valve abnormalities.
Laboratory Assessments:
Positive test result for drugs of abuse (including marijuana), alcohol, or cotinine at Screening or before the first study dose.
Prior/Concomitant Therapy:
Participants were unable to refrain from using prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's wort), within 7 days prior to the first dose and throughout the study.
Levothyroxine and omeprazole were allowed if participants had been on a stable dose for >= 1 month prior to Treatment Period 1 and maintained the same dose. Microgynon was administered >= 1 hour after levothyroxine or omeprazole. Other medications were allowed on a case-by-case basis with medical monitor and GSK ganfeborole team approval.
Participants who had undergone IVF or assisted reproductive techniques within 9 months prior to screening, were currently participating, or planned such procedures during the following year were excluded.
Prior/Concurrent Clinical Study Experience:
Study participation resulted in donation of blood or blood products > 500 mL within 56 days.
Diagnostic Assessments:
Exclusion criteria for screening ECG:
Heart rate \< 50 or > 100 bpm
interval > 450 ms
Other Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a dose of Microgynon \[0.03 mg Ethinyl Estradiol (EE)/0.15 mg Levonorgestrel (LNG)\] on Day 1 of Treatment Period 1. In Treatment Period 2, they received GSK3036656 40 mg on Day 4 followed by GSK3036656 20 mg once daily from Day 5 to Day 14. In Treatment Period 3, participants received Microgynon (EE/LNG) along with GSK3036656 20 mg on Day 15, followed by GSK3036656 20 mg once daily from Day 16 to Day 17.
Drug: Microgynon · Drug: GSK3036656
Participants received 1 dose of Microgynon (0.03 mg EE/0.15 mg LNG) on Day 1 of Treatment Period 1 and 1 dose co-administered with GSK3036656 20 mg on Day 15 of Treatment Period 3.
Participants received 1 loading dose of 40 mg on Day 4 and a dose of 20 mg on Days 5 to 14 once daily in Treatment Period 2. In Treatment Period 3, participants received one 20 mg dose along with Microgynon (0.03 mg EE/0.15 mg LNG) on Day 15 after which a 20 mg dose on Days 17 and 18 once daily.
Area Under the Plasma Drug Concentration (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) After a Single Dose of EE and LNG
AUC(0-inf) is defined as the area under the concentration-time curve from time 0 extrapolated to infinity and was calculated by using a non-compartmental analysis.
Time frame: At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group
Maximum Observed Plasma Concentration (Cmax) After a Single Dose of EE and LNG
Cmax is defined as the maximum observed plasma concentration determined directly from the concentration-time data and was calculated by using a non-compartmental analysis.
Time frame: At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group
AUC Versus Time Curve From Time Zero During a Dosage Interval of Time at Steady State [AUC(0-tau)] of GSK3036656 With EE/LNG
AUC(0-tau) is defined as the area under the concentration-time curve over a dosing interval and was calculated by using a non-compartmental analysis.
Time frame: At Day 15
Cmax at Steady State of GSK3036656 With EE/LNG
Cmax is defined as the maximum observed plasma concentration determined directly from the concentration-time data and was calculated by using a non-compartmental analysis.
Time frame: At Day 15
Trough Plasma Concentration (Ctau) at Steady State of GSK3036656 With EE/LNG and GSK3036656 Alone
Ctau is defined as the concentration reached by the drug immediately before the next dose is administered.
Time frame: At Day 8, 10, 12, 15 and 16
Time to Maximum Observed Plasma Drug Concentration (Tmax) at Steady State of GSK3036656 With EE/LNG
Tmax is defined as a measure of the time required to reach the maximum concentration of the drug, determined directly from the concentration-time data.
Time frame: At Day 15
AUC Versus Time Curve (AUC[0-t]) of EE and LNG Alone and With GSK3036656
AUC(0-t) is defined as area under the plasma drug concentration versus time curve from time zero (pre-dose) to last time of quantifiable concentration and was calculated by using a non-compartmental analysis.
Time frame: At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group
Tmax of EE and LNG Alone and With GSK3036656
Tmax is defined as a measure of the time required to reach the maximum concentration of the drug, determined directly from the concentration-time data.
Time frame: At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group
Apparent Terminal Half-life (t1/2) of EE and LNG Alone and With GSK3036656
t1/2 is defined as the time required by the plasma concentration to decline by 50% and was calculated by using a non-compartmental analysis.
Time frame: At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group
Number of Participants With Serious Adverse Events (SAEs)
A SAE is defined as any untoward medical occurrence that, at any dose: resulted in death, was life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment.
Time frame: From the signing of the informed consent form (a period starting up to 14 days before the first dose on Day 1) up to Day 18
Number of Participants With Grade 3 or Higher Severity Adverse Events (AEs)
The intensity of AEs was assessed using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1 where grades are defined based on numeric criteria as follows Grade 3: severe or medically significant; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicates greater severity.
Time frame: From Day 1 up to Day 18
Number of Participants With Drug-related AEs Following Administration of Microgynon and Following the Administration of GSK3036656
The drug-related AEs were assessed by the investigator to be possibly, probably or definitely related to the study interventions.
Time frame: From Day 1 up to Day 18
Number of Participants Withdrawn From the Treatment Due to AEs
Adverse events resulting in withholding of study intervention administration were included in this outcome measure.
Time frame: From Day 1 up to Day 18
Number of Participants Withdrawn From the Study Due to AEs
Time frame: From Day 1 up to Day 18
Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Importance (PCI)
PCI ECG values are defined as any ECG findings which, in the opinion of the investigator or medical monitor would interfere with the safety of the individual participant. The ECG measurements analyzed are PR Interval, QRS Duration, and QTcF Interval. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.
Time frame: From Day 1 up to Day 18
Number of Participants With Clinical Chemistry Laboratory Values of PCI
The chemistry parameters analyzed are homocysteine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), direct bilirubin, bilirubin, calcium, creatine kinase, potassium, protein, sodium, urea, and glucose. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.
Time frame: From Day 1 up to Day 18
Number of Participants With Haematology Laboratory Values of PCI
The analyzed hematology parameters are reticulocytes/erythrocytes, monocytes/leukocytes, erythrocytes, basophils/leukocytes, eosinophils/leukocytes, mean corpuscular hemoglobin, hematocrit, hemoglobin, lymphocytes, neutrophils, and platelets. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.
Time frame: From Day 1 up to Day 18
Number of Participants With Vital Signs Parameters of PCI
The analyzed vital signs are systolic blood pressure, diastolic blood pressure, heart rate, body temperature, and respiration rate. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.
Time frame: From Day 1 up to Day 18
| Milestone | Combined Participants Group |
|---|---|
| Started | 20 |
| Completed | 19 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Combined Participants Group |
|---|---|
| Started | 19 |
| Completed | 18 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
| Milestone | Combined Participants Group |
|---|---|
| Started | 18 |
| Completed | 18 |
| Not completed | 0 |
AUC(0-inf) is defined as the area under the concentration-time curve from time 0 extrapolated to infinity and was calculated by using a non-compartmental analysis.
| hour*picogram per milliliter (h*pg/mL) | Treatment Period 1: Microgynon Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|
| EE, Day 1 | 627.11 ± 53.0 | — |
| EE, Day 15 | — | 552.01 ± 51.0 |
| LNG, Day 1 | 24651.76 ± 113.2 | — |
| LNG, Day 15 | — | 30334.48 ± 94.2 |
Cmax is defined as the maximum observed plasma concentration determined directly from the concentration-time data and was calculated by using a non-compartmental analysis.
| picogram per milliliter (pg/mL) | Treatment Period 1: Microgynon Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|
| EE, Day 1 | 50.86 ± 32.7 | — |
| EE, Day 15 | — | 48.96 ± 24.5 |
| LNG, Day 1 | 2599.85 ± 46.8 | — |
| LNG, Day 15 | — | 2828.17 ± 45.3 |
AUC(0-tau) is defined as the area under the concentration-time curve over a dosing interval and was calculated by using a non-compartmental analysis.
| hour*nanogram per milliliter (h*ng/mL) | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|
| AUC Versus Time Curve From Time Zero During a Dosage Interval of Time at Steady State [AUC(0-tau)] of GSK3036656 With EE/LNG | 8372.42 ± 18.8 |
Cmax is defined as the maximum observed plasma concentration determined directly from the concentration-time data and was calculated by using a non-compartmental analysis.
| nanogram per milliliter (ng/mL) | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|
| Cmax at Steady State of GSK3036656 With EE/LNG | 600.62 ± 14.2 |
Ctau is defined as the concentration reached by the drug immediately before the next dose is administered.
| ng/mL | Treatment Period 2: GSK3036656 Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|
| Day 8 | 226.92 ± 17.9 | — |
| Day 10 | 235.54 ± 27.5 | — |
| Day 12 | 243.40 ± 21.9 | — |
| Day 15 | — | 251.26 ± 40.3 |
| Day 16 | — | 254.91 ± 23.0 |
Tmax is defined as a measure of the time required to reach the maximum concentration of the drug, determined directly from the concentration-time data.
| hour | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|
| Time to Maximum Observed Plasma Drug Concentration (Tmax) at Steady State of GSK3036656 With EE/LNG | 0.95 (0.4 to 3.0) |
AUC(0-t) is defined as area under the plasma drug concentration versus time curve from time zero (pre-dose) to last time of quantifiable concentration and was calculated by using a non-compartmental analysis.
| h*pg/mL | Treatment Period 1: Microgynon Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|
| EE, Day 1 | 447.10 ± 58.7 | — |
| EE, Day 15 | — | 363.00 ± 43.4 |
| LNG, Day 1 | 21182.61 ± 84.3 | — |
| LNG, Day 15 | — | 23287.77 ± 91.3 |
Tmax is defined as a measure of the time required to reach the maximum concentration of the drug, determined directly from the concentration-time data.
| hour | Treatment Period 1: Microgynon Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|
| EE, Day 1 | 0.967 (0.47 to 2.97) | — |
| EE, Day 15 | — | 1.433 (0.45 to 3.05) |
| LNG, Day 1 | 0.967 (0.92 to 1.93) | — |
| LNG, Day 15 | — | 0.967 (0.45 to 2.07) |
t1/2 is defined as the time required by the plasma concentration to decline by 50% and was calculated by using a non-compartmental analysis.
| hour | Treatment Period 1: Microgynon Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|
| EE, Day 1 | 19.180 (4.38 to 49.03) | — |
| EE, Day 15 | — | 10.867 (3.14 to 29.39) |
| LNG, Day 1 | 41.315 (4.00 to 100.00) | — |
| LNG, Day 15 | — | 34.697 (4.17 to 118.18) |
A SAE is defined as any untoward medical occurrence that, at any dose: resulted in death, was life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment.
| Participants | Treatment Period 1: Microgynon Group | Treatment Period 2: GSK3036656 Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 0 | 0 | 0 |
The intensity of AEs was assessed using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1 where grades are defined based on numeric criteria as follows Grade 3: severe or medically significant; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicates greater severity.
| Participants | Treatment Period 1: Microgynon Group | Treatment Period 2: GSK3036656 Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|---|
| Number of Participants With Grade 3 or Higher Severity Adverse Events (AEs) | 0 | 0 | 0 |
The drug-related AEs were assessed by the investigator to be possibly, probably or definitely related to the study interventions.
| Participants | Treatment Period 1: Microgynon Group | Treatment Period 2: GSK3036656 Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|---|
| Number of Participants With Drug-related AEs Following Administration of Microgynon and Following the Administration of GSK3036656 | 0 | 0 | 0 |
Adverse events resulting in withholding of study intervention administration were included in this outcome measure.
| Participants | Treatment Period 1: Microgynon Group | Treatment Period 2: GSK3036656 Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|---|
| Number of Participants Withdrawn From the Treatment Due to AEs | 0 | 1 | 0 |
| Participants | Treatment Period 1: Microgynon Group | Treatment Period 2: GSK3036656 Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|---|
| Number of Participants Withdrawn From the Study Due to AEs | 0 | 1 | 0 |
PCI ECG values are defined as any ECG findings which, in the opinion of the investigator or medical monitor would interfere with the safety of the individual participant. The ECG measurements analyzed are PR Interval, QRS Duration, and QTcF Interval. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.
| Participants | Treatment Period 1: Microgynon Group | Treatment Period 2: GSK3036656 Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|---|
| PR Interval, To Low | 0 | 0 | 0 |
| PR Interval, To W/in Range or No Change | 20 | 19 | 18 |
| PR Interval, To High | 0 | 0 | 0 |
| QRS Duration, To Low | 3 | 1 | 3 |
| QRS Duration, To W/in Range or No Change | 17 | 18 | 15 |
| QRS Duration, To High | 0 | 0 | 0 |
| QTcF Interval, To Low | 0 | 0 | 0 |
| QTcF Interval, To W/in Range or No Change | 20 | 19 | 18 |
| QTcF Interval, To High | 0 | 0 | 0 |
The chemistry parameters analyzed are homocysteine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), direct bilirubin, bilirubin, calcium, creatine kinase, potassium, protein, sodium, urea, and glucose. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.
| Participants | Treatment Period 1: Microgynon Group | Treatment Period 2: GSK3036656 Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|---|
| Homocysteine, To Low | 0 | 0 | 0 |
| Homocysteine, To W/in Range or No Change | 19 | 19 | 15 |
| Homocysteine, To High | 1 | 0 | 3 |
| ALT, To Low | 0 | 0 | 0 |
| ALT, To W/in Range or No Change | 20 | 19 | 18 |
| ALT, To High | 0 | 0 | 0 |
| AST, To Low | 0 | 0 | 0 |
| AST, To W/in Range or No Change | 20 | 16 | 15 |
| AST, To High | 0 | 0 | 0 |
| Direct Bilirubin, To Low | 0 | 0 | 0 |
| Direct Bilirubin, To W/in Range or No Change | 20 | 17 | 17 |
| Direct Bilirubin, To High | 0 | 1 | 0 |
| Bilirubin, To Low | 0 | 0 | 0 |
| Bilirubin, To W/in Range or No Change | 20 | 18 | 17 |
| Bilirubin, To High | 0 | 0 | 0 |
| Calcium, To Low | 0 | 0 | 0 |
| Calcium, To W/in Range or No Change | 20 | 19 | 18 |
| Calcium, To High | 0 | 0 | 0 |
| Creatine Kinase, To Low | 0 | 0 | 0 |
| Creatine Kinase, To W/in Range or No Change | 20 | 18 | 18 |
| Creatine Kinase, To High | 0 | 1 | 0 |
| Potassium, To Low | 0 | 0 | 0 |
| Potassium, To W/in Range or No Change | 20 | 16 | 15 |
| Potassium, To High | 0 | 0 | 0 |
| Protein, To Low | 0 | 0 | 0 |
| Protein, To W/in Range or No Change | 20 | 19 | 18 |
| Protein, To High | 0 | 0 | 0 |
| Sodium, To Low | 0 | 0 | 0 |
| Sodium, To W/in Range or No Change | 20 | 19 | 18 |
| Sodium, To High | 0 | 0 | 0 |
| Urea, To Low | 0 | 0 | 0 |
| Urea, To W/in Range or No Change | 19 | 19 | 18 |
| Urea, To High | 1 | 0 | 0 |
| Glucose, To Low | 0 | 0 | 0 |
| Glucose, To W/in Range or No Change | 19 | 18 | 18 |
| Glucose, To High | 0 | 0 | 0 |
The analyzed hematology parameters are reticulocytes/erythrocytes, monocytes/leukocytes, erythrocytes, basophils/leukocytes, eosinophils/leukocytes, mean corpuscular hemoglobin, hematocrit, hemoglobin, lymphocytes, neutrophils, and platelets. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.
| Participants | Treatment Period 1: Microgynon Group | Treatment Period 2: GSK3036656 Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|---|
| Basophils/Leukocytes, To Low | 7 | 1 | 1 |
| Basophils/Leukocytes, To W/in Range or No Change | 13 | 17 | 16 |
| Basophils/Leukocytes, To High | 0 | 0 | 0 |
| Eosinophils/Leukocytes, To Low | 1 | 0 | 2 |
| Eosinophils/Leukocytes, To W/in Range or No Change | 19 | 14 | 15 |
| Eosinophils/Leukocytes, To High | 0 | 4 | 0 |
| Monocytes/Leukocytes, To Low | 0 | 0 | 0 |
| Monocytes/Leukocytes, To W/in Range or No Change | 20 | 17 | 17 |
| Monocytes/Leukocytes, To High | 0 | 1 | 0 |
| Erythrocytes, To Low | 0 | 5 | 0 |
| Erythrocytes, To W/in Range or No Change | 20 | 13 | 17 |
| Erythrocytes, To High | 0 | 0 | 0 |
| Reticulocytes/Erythrocytes, To Low | 0 | 0 | 0 |
| Reticulocytes/Erythrocytes, To W/in Range or No Change | 19 | 16 | 16 |
| Reticulocytes/Erythrocytes, To High | 1 | 2 | 1 |
| Mean Corpuscular Hemoglobin, To Low | 0 | 0 | 0 |
| Mean Corpuscular Hemoglobin, To W/in Range or No Change | 20 | 18 | 17 |
| Mean Corpuscular Hemoglobin, To High | 0 | 0 | 0 |
| Hematocrit, To Low | 0 | 0 | 0 |
| Hematocrit, To W/in Range or No Change | 20 | 18 | 17 |
| Hematocrit, To High | 0 | 0 | 0 |
| Hemoglobin, To Low | 0 | 0 | 0 |
| Hemoglobin, To W/in Range or No Change | 20 | 18 | 17 |
| Hemoglobin, To High | 0 | 0 | 0 |
| Lymphocytes, To Low | 0 | 0 | 0 |
| Lymphocytes, To W/in Range or No Change | 20 | 18 | 17 |
| Lymphocytes, To High | 0 | 0 | 0 |
| Neutrophils, To Low | 0 | 0 | 0 |
| Neutrophils, To W/in Range or No Change | 20 | 18 | 17 |
| Neutrophils, To High | 0 | 0 | 0 |
| Platelets, To Low | 0 | 0 | 0 |
| Platelets, To W/in Range or No Change | 20 | 18 | 17 |
| Platelets, To High | 0 | 0 | 0 |
The analyzed vital signs are systolic blood pressure, diastolic blood pressure, heart rate, body temperature, and respiration rate. A value was reported as "high" for a period if it shifted from "low" or "within range" (W/in) at the start of the treatment period but was "high" during or at the end of the same treatment period. A value was reported as "low" for a period if it shifted from "high" or "W/in" at the start of the treatment period but was "low" during or at the end of the same treatment period. A value was reported as "No Change" if it remained unchanged (e.g. High to High), or as "To W/in Range" if it was within range.
| Participants | Treatment Period 1: Microgynon Group | Treatment Period 2: GSK3036656 Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|---|
| Diastolic Blood Pressure, To Low | 0 | 0 | 0 |
| Diastolic Blood Pressure, To w/in Range or No Change | 20 | 19 | 18 |
| Diastolic Blood Pressure, To High | 0 | 0 | 0 |
| Pulse Rate, To Low | 0 | 0 | 0 |
| Pulse Rate, To w/in Range or No Change | 20 | 19 | 18 |
| Pulse Rate, To High | 0 | 0 | 0 |
| Respiratory Rate, To Low | 0 | 0 | 0 |
| Respiratory Rate, To w/in Range or No Change | 20 | 19 | 18 |
| Respiratory Rate, To High | 0 | 0 | 0 |
| Systolic Blood Pressure, To Low | 0 | 0 | 0 |
| Systolic Blood Pressure, To w/in Range or No Change | 20 | 19 | 18 |
| Systolic Blood Pressure, To High | 0 | 0 | 0 |
| Temperature, To Low | 0 | 0 | 0 |
| Temperature, To w/in Range or No Change | 20 | 19 | 18 |
| Temperature, To High | 0 | 0 | 0 |
Collected over Adverse Events were reported from Day 1 (first study dose) up to Day 18. Serious Adverse Events were reported from the signing of the informed consent form (a period starting up to 14 days before the first dose on Day 1) up to Day 18. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Period 1: Microgynon Group | 0/20 (0%) | 0/20 (0%) | 4/20 (20%) |
| Treatment Period 2: GSK3036656 Group | 0/19 (0%) | 0/19 (0%) | 1/19 (5.3%) |
| Treatment Period 3: Microgynon + GSK3036656 Group | 0/18 (0%) | 0/18 (0%) | 1/18 (5.6%) |
| Event | Treatment Period 1: Microgynon Group | Treatment Period 2: GSK3036656 Group | Treatment Period 3: Microgynon + GSK3036656 Group |
|---|---|---|---|
| HeadacheNervous system disorders | 4/20 | 0/19 | 1/18 |
| ToothacheGastrointestinal disorders | 0/20 | 1/19 | 0/18 |
| Age, Continuous(YEARS) | Combined Participants Group |
|---|---|
| Mean | 53.6 ± 5.64 |
| Sex: Female, Male(Participants) | Combined Participants Group |
|---|---|
| Female | 20 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | Combined Participants Group |
|---|---|
| WHITE | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Apr 2024 to primary completion in Jul 2024, 2 months.
Results were first posted in Aug 2025, 1 year 1 month after primary completion.
Of 60 phase 1 interventional studies under Tuberculosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK656